EMA expands the number of people who can be vaccinated with Evesheld to prevent Covid-19

Accordingly, the users are people over 12 years old and weighing 40kg or more, regardless of the medical condition or not.

This decision is based on the recommendation to use Evusheld from the Provent clinical study – the world’s leading prestigious study, opening the door for more groups of people to be protected against Covid-19. In particular, especially the group at high risk of infection and at high risk of severe disease and death, such as the elderly, people with underlying medical conditions, people who often come into contact with many people or perform essential services, work or do other work. anti-epidemic…

Widespread injection of Evesheld is expected to help limit the risk of Covid-19 infection and severe disease for the majority of the population. Photo: Tam Anh General Hospital

This approval is said to be in line with the fact that population groups aged 65 years and over, suffering from one or more chronic diseases at the same time such as cancer, cardiovascular disease, chronic respiratory disease, diabetes, mental illness, etc. This is a group of people who are prone to severe illness and death when infected with Covid-19.

Experiments from the University of Washington School of Medicine in the laboratory showed that Evusheld was able to neutralize the contagious BA.2 sub-variant. This live organism trial also showed that Evusheld reduced the viral load detected in samples of all Omicron subvariants tested, limiting pneumonia to the BA subvariants. .1, BA.1.1 and BA.2 of Omicron.

Mene Pangalos, Executive Vice President, BioPharmaceutical R&D, AstraZeneca, said: “Evusheld has the potential to provide long-term protection against Covid-19 for a large population that is not yet fully protected by vaccines. apply for Covid-19 prevention, as well as those at high risk of exposure.”

In Vietnam, after 1 week of administering Evusheld injections at Tam Anh General Hospital in Hanoi and Tam Anh General Hospital in Ho Chi Minh City, thousands of people have been injected, with stable health after injection.

The bringing of the monoclonal Evusheld antibody against Covid-19 to Vietnam by the VNVC Immunization Center System and the Tam Anh General Hospital System is considered an important step forward in the prevention of Covid-19, contributing to opening the door. effectively protect groups of people at high risk of infection, severe disease and death, especially in the face of the risk of rapid spread of the Omicron variant, leaving the burden of post-Covid-19 sequelae for the community and the industry. medican.

Tam Anh General Hospital in Ho Chi Minh City has recently given people an injection of Evesheld to prevent Covid-19 from spreading. Photo: Tam Anh General Hospital

A close combination of rapid, comprehensive roll-out of the Covid-19 vaccine and the monoclonal anti-Evusheld is expected to be effective, while ensuring all communities are protected.

Previously, on February 24, 2022, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Covid-19 prophylactic monoclonal antibody Evusheld manufactured by AstraZeneca. . After that, Evusheld was urgently licensed in many countries around the world such as: USA, Bahrain, France, United Arab Emirates…

Hoai An